Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Claritev CorporationNYSE: CTEV
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $111.65M rose 0.1% year over year, behind the +1.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Depreciation & amortization amounted to 46.5% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.1% toward the trailing-twelve-month pace of +1.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 448.45M USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- +2.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 448.45M | +2.8% |
| FY2024 | 2024-12-31 | 436.44M | +2.5% |
| FY2023 | 2023-12-31 | 425.79M | +2.4% |
| FY2022 | 2022-12-31 | 415.66M | +0.9% |
| FY2021 | 2021-12-31 | 412.06M | — |
Depreciation & Amortization vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 depreciation & amortization of $447.88M is the highest of the 11 companies compared; the peer median is $10.63M.
- Its year-over-year change of +1.8% is the 6th highest of 11, against a peer median of +0.2%.
- Depreciation & amortization amounts to 45.8% of revenue for CTEV, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $447.88M | +1.8% | +2.6% | 45.8% |
| LTM Mar 2026 | $152.29M | +3.3% | +7.6% | 9.3% | |
| LTM Mar 2026 | $118.75M | +4.1% | +8.7% | 6.3% | |
| LTM Mar 2026 | $90.34M | -5.7% | -5.5% | 15.5% | |
| LTM Mar 2026 | $86.1M | +15.6% | +16.3% | 10.9% | |
| LTM Mar 2026 | $11.49M | -33.5% | -6.6% | — | |
| LTM Mar 2026 | $9.76M | -2.9% | +88.7% | 4.4% | |
| LTM Sep 2026 | $8.91M | +19.5% | +19.1% | 3.3% | |
| LTM Mar 2026 | $2.05M | +160.3% | +52.5% | 2.4% | |
| LTM Mar 2026 | $696K | -5.6% | +0.7% | 0.2% | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| Peer median (excluding CTEV) | $10.63M | +0.2% | +12.5% | 6.3% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.12B | 1.08B | 961.52M | 930.62M | 965.41M |
| Cost of Revenue | 175.29M | 204.1M | 235.47M | 239.4M | 698.84M |
| Gross Profit | 942.31M | 875.62M | 726.06M | 691.22M | 266.58M |
| Gross Margin | 84.3% | 81.1% | 75.5% | 74.3% | 27.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 151.1M | 132.14M | 135.99M | 160.22M | 221.52M |
| Operating Expenses | 556.19M | 1.24B | 564.07M | 2.08B | 221.52M |
| Depreciation & Amortization | 412.06M | 415.66M | 425.79M | 436.44M | 448.45M |
| EBITDA | 814.99M | 158.32M | 651.93M | (1.01B) | 475.44M |
| EBITDA Margin | 72.9% | 14.7% | 67.8% | -108.3% | 49.2% |
| Operating Income | 386.12M | (362.73M) | 161.98M | (1.39B) | 45.06M |
| Operating Margin | 34.5% | -33.6% | 16.8% | -149.4% | 4.7% |
| Interest Income | 30K | 3.5M | 8.23M | 3.13M | 1.56M |
| Interest Expense | 267.48M | 303.4M | 333.21M | 326.37M | 400.07M |
| Other Income / Expenses | (250.67M) | (198.01M) | (269.04M) | (380.78M) | (418.14M) |
| Income Before Tax | 135.45M | (560.74M) | (107.06M) | (1.77B) | (373.08M) |
| Pre-Tax Margin | 12.1% | -51.9% | -11.1% | -190.3% | -38.6% |
| Income Tax Expense | 33.37M | 12.17M | (15.36M) | (124.88M) | (88.8M) |
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Net Margin | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% |
| EPS (Basic) | 6.40 | (35.87) | (5.69) | (101.92) | (17.30) |
| EPS (Diluted) | 6.40 | (35.87) | (5.69) | (101.92) | (17.30) |
| Weighted Avg Shares | 16.28M | 15.97M | 16.13M | 16.15M | 16.43M |
| Weighted Avg Shares (Diluted) | 16.29M | 15.97M | 16.13M | 16.15M | 16.43M |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.